Literature DB >> 35412162

Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L descriptive systems and utilities in atopic dermatitis.

Kamilla Koszorú1,2, Krisztina Hajdu3,4, Valentin Brodszky5, Alex Bató2,5, L Hunor Gergely1, Anikó Kovács1, Zsuzsanna Beretzky5, Miklós Sárdy1, Andrea Szegedi3,4, Fanni Rencz6.   

Abstract

BACKGROUND: Atopic dermatitis (AD) is a common chronic inflammatory skin disorder affecting up to 10% of adults. The EQ-5D is the most commonly used generic preference-accompanied measure to generate quality-adjusted life years (QALYs) for economic evaluations.
OBJECTIVES: We aimed to compare psychometric properties of the three-level and five-level EQ-5D (EQ-5D-3L and EQ-5D-5L) in adult patients with AD.
METHODS: In a multicentre cross-sectional study, 218 AD patients with a broad range of severity completed the EQ-5D-3L, EQ-5D-5L, Dermatology Life Quality Index (DLQI) and Skindex-16. Disease severity outcomes included the Investigator Global Assessment, Eczema Area and Severity Index and the objective SCORing Atopic Dermatitis.
RESULTS: A good agreement was established between the two EQ-5D versions with an intraclass correlation coefficient of 0.815 (95% CI 0.758-0.859, p < 0.001). Overall, 33 different health state profiles occurred in the EQ-5D-3L and 84 in the EQ-5D-5L. Compared to the EQ-5D-3L, ceiling effect was reduced for the mobility, self-care, usual activities and pain/discomfort dimensions by 4.6-11.5%. EQ-5D-5L showed higher average relative informativity (Shannon's evenness index: 0.64 vs. 0.59). EQ-5D-5L demonstrated better convergent validity with EQ VAS, DLQI and Skindex-16. The two measures were similar in distinguishing between groups of patients based on disease severity and skin-specific quality of life with a moderate or large effect size (η2 = 0.083-0.489).
CONCLUSION: Both instruments exhibited good psychometric properties in AD; however, the EQ-5D-5L was superior in terms of ceiling effects, informativity and convergent validity. We recommend the use of the EQ-5D-5L to measure health outcomes in clinical settings and for QALY calculations in AD.
© 2022. The Author(s).

Entities:  

Keywords:  Atopic dermatitis; EQ-5D-3L; EQ-5D-5L; Psychometrics; Utility

Year:  2022        PMID: 35412162     DOI: 10.1007/s10198-022-01460-y

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  62 in total

1.  Pregnancy complications, treatment characteristics and birth outcomes in women with atopic dermatitis in Denmark.

Authors:  C R Hamann; A Egeberg; A Wollenberg; G Gislason; L Skov; J P Thyssen
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-10-08       Impact factor: 6.166

2.  Reply to: "Comment on 'Review of patient registries in dermatology'".

Authors:  Gabriella DiMarco; Dane Hill; Steven R Feldman
Journal:  J Am Acad Dermatol       Date:  2016-12       Impact factor: 11.527

Review 3.  Atopic dermatitis.

Authors:  Stephan Weidinger; Lisa A Beck; Thomas Bieber; Kenji Kabashima; Alan D Irvine
Journal:  Nat Rev Dis Primers       Date:  2018-06-21       Impact factor: 52.329

4.  Impact of atopic dermatitis on quality of life in adults: a systematic review and meta-analysis.

Authors:  Gurkiran Birdi; Richard Cooke; Rebecca C Knibb
Journal:  Int J Dermatol       Date:  2020-01-13       Impact factor: 2.736

5.  Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.

Authors:  Lieneke F M Ariëns; Abhijit Gadkari; Harmieke van Os-Medendorp; Rajeev Ayyagari; Emi Terasawa; Andreas Kuznik; Zhen Chen; Gaëlle Bégo-Le Bagousse; Yufang Lu; Elena Rizova; Neil M H Graham; Gianluca Pirozzi; Marjolein De Bruin-Weller; Laurent Eckert
Journal:  Acta Derm Venereol       Date:  2019-09-01       Impact factor: 4.437

Review 6.  Atopic dermatitis: an expanding therapeutic pipeline for a complex disease.

Authors:  Thomas Bieber
Journal:  Nat Rev Drug Discov       Date:  2021-08-20       Impact factor: 84.694

Review 7.  Atopic dermatitis.

Authors:  Sinéad M Langan; Alan D Irvine; Stephan Weidinger
Journal:  Lancet       Date:  2020-08-01       Impact factor: 79.321

8.  Measurement properties of quality-of-life outcome measures for children and adults with eczema: An updated systematic review.

Authors:  Michaela Gabes; Christina Tischer; Christian Apfelbacher
Journal:  Pediatr Allergy Immunol       Date:  2019-10-18       Impact factor: 6.377

Review 9.  Quality of life in patients with atopic dermatitis.

Authors:  Kamilla Koszorú; Júlia Borza; László Gulácsi; Miklós Sárdy
Journal:  Cutis       Date:  2019-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.